Table 5 Postnatal follow-up to verify the accuracy of prenatal ultrasound screening
Congenital heart defect | Postnatal agreement with prenatal screening | Postnatal disagreement with prenatal screening | Number of cases followed up | Agreement (%) |
|---|---|---|---|---|
Postnatal imaging and surgery | ||||
VSD | 738 | 98 | 836 | 88·28% |
PLSVC | 133 | 4 | 137 | 97·08% |
ECD | 115 | 10 | 125 | 92·00% |
TOF | 112 | 22 | 134 | 83·58% |
CVR | 104 | 4 | 108 | 96·30% |
DORV | 91 | 10 | 101 | 90·10% |
TGA | 54 | 4 | 58 | 93·10% |
SV | 49 | 11 | 60 | 81·67% |
PS | 44 | 12 | 56 | 78·57% |
COA/IAA | 20 | 24 | 44 | 45·45% |
AS | 42 | 7 | 49 | 85·71% |
PTA | 38 | 11 | 49 | 77·55% |
PVS | 32 | 0 | 32 | 100·00% |
HS | 17 | 0 | 17 | 100·00% |
ASA | 16 | 6 | 22 | 72·73% |
Cardiac tumor | 14 | 1 | 15 | 93·33% |
HLHS | 25 | 3 | 28 | 89·29% |
EA | 10 | 2 | 12 | 83·33% |
Dextrocardia | 10 | 0 | 10 | 100·00% |
HRHS | 9 | 0 | 9 | 100·00% |
PA/VSD | 7 | 0 | 7 | 100·00% |
Dextrocardia | 7 | 0 | 7 | 100·00% |
TA | 6 | 0 | 6 | 100·00% |
Myocardiopathy | 5 | 0 | 5 | 100·00% |
DAS | 5 | 0 | 5 | 100·00% |
HRHS | 4 | 1 | 5 | 80·00% |
TVD | 4 | 0 | 4 | 100·00% |
TAPVD | 3 | 1 | 4 | 75·00% |
CAF | 3 | 0 | 3 | 100·00% |
CT | 3 | 1 | 4 | 75·00% |
MA | 2 | 0 | 2 | 100·00% |
PA | 2 | 1 | 3 | 66·67% |
AA | 2 | 0 | 2 | 100·00% |
DOLV | 1 | 0 | 1 | 100·00% |
PCDA | 1 | 0 | 1 | 100·00% |
PDA | 1 | 0 | 1 | 100·00% |
TVC | 1 | 0 | 1 | 100·00% |
NVM | 0 | 1 | 1 | 0·00% |
AVS | 0 | 1 | 1 | 0·00% |
Subtotal | 1 = 730 | 235 | 1,965 | 88·04% |
Autopsy of aborted fetus | ||||
VSD | 621 | 53 | 674 | 92·14% |
ECD | 219 | 15 | 234 | 93·59% |
TOF | 153 | 21 | 174 | 87·93% |
DORV | 145 | 16 | 161 | 90·06% |
TGA | 111 | 9 | 120 | 92·50% |
PTA | 54 | 19 | 73 | 73·97% |
PA | 30 | 19 | 49 | 61·22% |
COA/IAA | 24 | 30 | 54 | 44·44% |
SV | 29 | 1 | 30 | 96·67% |
Cardiac tumor | 25 | 3 | 28 | 89·29% |
HS | 22 | 0 | 22 | 100·00% |
HLHS | 22 | 0 | 22 | 100·00% |
HRHS | 13 | 0 | 13 | 100·00% |
Subtotal | 1,468 | 186 | 1,654 | 88·75% |
Total | 3,198 | 421 | 3,619 | 88·37% |